• Título: Positive Three-Year Results from the Ovation® European Post Market Registry Presented at 2017 LINC Symposium
  • Fecha: 25-01-2017

  • IRVINE, Calif., Jan. 25, 2017 (GLOBE NEWSWIRE)
    -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of
    innovative treatments for aortic disorders, announced today the presentation of positive 3-year clinical data from
    the Ovation European Post Market Registry at the 2017 Leipzig Interventional Course (LINC Symposium) in
    Leipzig, Germany. The results were presented by Patrick Peeters, MD, Chief, Department of Cardiovascular
    Surgery, Imelda Hospital, Bonheiden, Belgium and investigator for the study.
    The Ovation European Post Market Registry included a total of 501 patients, enrolled across 30 European centers
    from May 2011 to December 2013. Through three years of follow-up, key highlights of the study results included:
    Broadest range of patient applicability on IFU of all commercially available infrarenal endovascular AAA devices

    99% freedom from aneurysm-
    related mortality

    99% freedom from migration, rupture, and conversion

    97% freedom from Type I/III endoleak

    Excellent freedom from secondary intervention for occlusion (97%), Type I endoleak (97%) and Type II
    Professor Dierk Scheinert, MD, study Principal Investigator and Chairman of the LINC Symposium commented,
    "This study confirms the ability of the Ovation platform to successfully treat
    a broad array of patient anatomies
    a high
    of treatment success and freedom from secondary intervention through mid-term follow-up. We
    are pleased to have revealed these impressive results at our scientific symposium this year."
    John McDermott, Chief Executive Officer of Endologix, said, "The addition of these European results continue to
    validate the excellent clinical results and durability of the ultra-low profile Ovation platform, further confirming
    the recently announced 5-year Ovation IDE study results with real-world commercial data. We would like to
    thank Dr. Scheinert, Dr. Peeters, and all of the investigators for their participation in this important clinical study
    and congratulate them for their outstanding results."
    About LINC
    The LEIPZIG INTERVENTIONAL COURSE is strongly committed to contribute to a systematic scientific evaluation
    and interdisciplinary discussion of new methods, allowing conclusions for daily interventional practice. LINC is an
    interdisciplinary live course, designed to provide a global platform, permitting the discussion of the vascular
    patients by integrating colleagues of different specialties who are performing endovascular interventions.

    About Endologix, Inc.
    Endologix, Inc., develops and manufactures minimally invasive treatments for aortic disorders. The Company's
    focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of
    the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it
    continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient
    mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the United States.
    Additional information can be found on Endologix's website at
    Forward Looking Statements
    This communication includes statements that may be "forward-looking statements" within the meaning of the
    Private Securities Litigation Reform Act of 1995, including with respect to clinical results obtained with Endologix's
    Ovation platform, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult
    or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may
    cause actual results to differ materially from anticipated results, including unanticipated clinical outcomes. Undue
    reliance should not be placed on forward-looking statements, which speak only as of the date they are made.
    Endologix undertakes no obligation to update any forward looking statements to reflect new information, events
    or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer
    to Endologix's Annual Report on Form 10-K for the year ended December 31, 2015, and Endologix's subsequent
    filings with the Securities and Exchange Commission, for more detailed information regarding these risks and
    other factors
    that may cause actual results to differ materially from those expressed or implied.

  • Fuente: